Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials

Frits van Rhee, Corey Casper, Peter M. Voorhees, Luis E. Fayad, Damilola Gibson, Karan Kanhai, Razelle Kurzrock

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Fingerprint

Dive into the research topics of 'Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials'. Together they form a unique fingerprint.

Medicine & Life Sciences